Nothing Special   »   [go: up one dir, main page]

AR092971A1 - Inhibidores de agrecanasa - Google Patents

Inhibidores de agrecanasa

Info

Publication number
AR092971A1
AR092971A1 ARP130103679A ARP130103679A AR092971A1 AR 092971 A1 AR092971 A1 AR 092971A1 AR P130103679 A ARP130103679 A AR P130103679A AR P130103679 A ARP130103679 A AR P130103679A AR 092971 A1 AR092971 A1 AR 092971A1
Authority
AR
Argentina
Prior art keywords
agrecanasa
inhibitors
cyclopropyl
intermediates
propyl
Prior art date
Application number
ARP130103679A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR092971A1 publication Critical patent/AR092971A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/76Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/417Imidazole-alkylamines, e.g. histamine, phentolamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/76Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a compuestos que tienen la fórmula (1) en donde R¹ se selecciona a partir de metilo, etilo, propilo, ciclopropilo, y dimetilo, o una sal de los mismos farmacéuticamente aceptable, junto con métodos e intermediarios para su preparación, y usos de los mismos.
ARP130103679A 2012-10-26 2013-10-10 Inhibidores de agrecanasa AR092971A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261718965P 2012-10-26 2012-10-26

Publications (1)

Publication Number Publication Date
AR092971A1 true AR092971A1 (es) 2015-05-06

Family

ID=49515523

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103679A AR092971A1 (es) 2012-10-26 2013-10-10 Inhibidores de agrecanasa

Country Status (20)

Country Link
US (1) US9206139B2 (es)
EP (1) EP2912021B1 (es)
JP (1) JP6251279B2 (es)
KR (1) KR101689983B1 (es)
CN (1) CN104755464B (es)
AR (1) AR092971A1 (es)
AU (1) AU2013334989B2 (es)
BR (1) BR112015009032B1 (es)
CA (1) CA2886526C (es)
DK (1) DK2912021T3 (es)
EA (1) EA026037B1 (es)
ES (1) ES2645970T3 (es)
HK (1) HK1211927A1 (es)
HU (1) HUE034616T2 (es)
MX (1) MX364207B (es)
NZ (1) NZ706772A (es)
PL (1) PL2912021T3 (es)
PT (1) PT2912021T (es)
TW (1) TWI620738B (es)
WO (1) WO2014066151A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015332370B2 (en) 2014-10-16 2019-09-19 Monsanto Technology Llc Lepidopteran-active Cry1Da1 amino acid sequence variant proteins
JO3501B1 (ar) 2014-12-22 2020-07-05 Servier Lab مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام)
GB201610056D0 (en) 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
GB201610055D0 (en) * 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
WO2021011723A1 (en) * 2019-07-18 2021-01-21 Avidence Therapeutics, Inc. Anti-osteoarthritis hydantoin compounds and related compositions and methods
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
US20230201208A1 (en) * 2020-04-20 2023-06-29 St. Jude Children's Research Hospital Composition and methods for treating respiratory diseases
WO2022007866A1 (zh) * 2020-07-09 2022-01-13 深圳信立泰药业股份有限公司 并三环类衍生物、其制备方法及其在医药上的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234028D1 (de) * 2001-05-25 2009-11-26 Bristol Myers Squibb Co Hydantion-derivate als hemmer von matrix-metalloproteinasen
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
AU2006261715A1 (en) * 2005-06-27 2007-01-04 Amgen Inc. Anti-inflammatory aryl nitrile compounds
CN101223130A (zh) * 2005-07-11 2008-07-16 惠氏公司 谷氨酸聚蛋白多糖酶抑制剂
AR059036A1 (es) * 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
BR112015009032A2 (pt) 2017-07-04
CA2886526C (en) 2018-03-27
EA201590621A1 (ru) 2015-07-30
TWI620738B (zh) 2018-04-11
MX364207B (es) 2019-04-16
PT2912021T (pt) 2017-11-14
KR101689983B1 (ko) 2016-12-26
DK2912021T3 (en) 2017-10-02
CN104755464A (zh) 2015-07-01
EP2912021B1 (en) 2017-08-16
AU2013334989B2 (en) 2016-02-18
KR20150058480A (ko) 2015-05-28
ES2645970T3 (es) 2017-12-11
HUE034616T2 (en) 2018-02-28
MX2015005297A (es) 2015-07-17
EP2912021A1 (en) 2015-09-02
CN104755464B (zh) 2017-03-29
US9206139B2 (en) 2015-12-08
NZ706772A (en) 2018-05-25
WO2014066151A1 (en) 2014-05-01
TW201427955A (zh) 2014-07-16
JP6251279B2 (ja) 2017-12-20
EA026037B1 (ru) 2017-02-28
AU2013334989A1 (en) 2015-04-23
US20150218107A1 (en) 2015-08-06
BR112015009032B1 (pt) 2022-06-28
PL2912021T3 (pl) 2018-01-31
CA2886526A1 (en) 2014-05-01
HK1211927A1 (en) 2016-06-03
JP2015535248A (ja) 2015-12-10

Similar Documents

Publication Publication Date Title
AR092971A1 (es) Inhibidores de agrecanasa
CU20180059A7 (es) Compuestos inhibidores de la quinasa de unión a tank
CR20140259A (es) Compuestos novedosos de benzopirano, composiciones y usos de los mismos
CR20160098A (es) Polimorfo de los inhibidores de la syk
DK2812431T3 (da) Peptidblandinger til generering af multivirale ctl'er med bred specificitet
RS54873B1 (sr) Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
CR20140134A (es) Composiciones farmacéuticas
BR112013018875A2 (pt) métodos e composições para a preparação de noribogaína a partir de voacangina
BR112015022077A2 (pt) composto de pirazol-amida e usos medicinais do mesmo
DK2755481T3 (da) Anvendelse af alginatoligomerer til at forøge virkningerne af svampemidler
CR20150663A (es) Derivados de diazacarbazol como ligandos de tau para pet
CO6960548A2 (es) Polimorfos de arry-380, un inhibidor selectivo de herb2 y composiciones farmacéuticas que los contienen
BR112012018086A2 (pt) método para gerar vapor d'água
CL2014002986A1 (es) Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.
AR095097A1 (es) Compuestos de fenoxietoxi
BR112012031861A2 (pt) uso de 5a-androstano (alquil)-3b, 5, 6b-triol
CO7010828A2 (es) Preparación farmacéutica que comprende ߖciclodextrina sustituida
CR20130375A (es) Preparaciones que contienen antraquinona/formulaciones de lignina
FR2973378B1 (fr) Derives d'acide hydroxybisphosphonique bifonctionnels
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
AR092627A1 (es) Derivados glucopiranosidos de urea

Legal Events

Date Code Title Description
FG Grant, registration